Psychedelics are marketed as a way for the general population to extract more work out of their already overworked lives, and to be happy about it in the process.
Articles on Psychedelics
Displaying 21 - 40 of 74 articles
Researchers in American scanned the ‘hell out of’ participants brains while they tripped on mushrooms.
There are fundamental flaws in psychedelics research. But I’m still intrigued by their potential.
Cannabis and psilocybin – used under supervision – have the potential to work better than current pain treatments, but the research into both has long been hindered by federal legislation.
People with personality disorders more likely to have a bad trip on psychedelics.
Psychedelic drug takers are sharing advice on Reddit on how to end a bad trip. Some of the advice is highly suspect.
One in seven Canadian veterans is living with PTSD. Developing a psychedelics research program for veterans should be a public health priority.
Can psychedelics assist in recovery from eating disorders? The findings are promising, but patients and doctors need to proceed with caution until there is additional and extensive research.
Clinical psychologist and professor Monnica Williams is on a mission to bring psychedelics to therapists’ offices to help people heal from their racial traumas. To do this, she’s jumping over some big hurdles.
Psychedelics are an opportunity to do better than our past drug control strategies. Adults should be trusted to make the right decisions, but policymakers should ensure they do so fully informed.
Change in the brain usually comes with plenty of effort over time. Neuroscientists are working to understand how psychedelic drugs provide a shortcut that seems to rely on existing brain systems.
Combining psychotherapy with medication can lead to more immediate and enduring results by boosting the brain’s neuroplasticity.
We still don’t know a lot about how the networks of cells in the brain enable conscious experience.
A scholar of religion who is writing a book on sacred drugs explains how today’s ‘psychedelic renaissance’ reflects a millennia-long history of using intoxicants to seek insight and connection.
This latest research provides hope for people whose symptoms are harder to treat.
In addition to placebo effects, patients might be motivated to report they have gotten better, even when they haven’t.
From July 1, authorised psychiatrists will be able to prescribe MDMA and psilocybin in some circumstances. Here’s what we’re excited and concerned about.
An anthropology course explores how peoples and cultures around the world use nature-based medicines to heal.
Australia is the first country in the world to legalise the medical use of psychedelics. But without a public subsidy, few Australians will be able to afford them.
Receiving a cancer diagnosis and undergoing cancer treatment can be a traumatizing experience. Psychedelics like LSD, psilocybin and MDMA could help alleviate symptoms from cancer-related PTSD.
Top contributors
-
Senior Lecturer of Addiction, Edith Cowan University
-
PhD Candidate, Congnitive Neuroscience, University of Toronto
-
PhD student in Clinical Psychology, York University, Canada
-
Associate Professor, Cognitive Psychology, Leiden University
-
Director, Executive Leadership Academy, University of California, Berkeley
-
Professor and Canada Research Chair in the History of Health & Social Justice, University of Saskatchewan
-
Distinguished Professor of Neurology and Psychiatry, Director of Psychedelics Division at Neuroscape, University of California, San Francisco
-
Research fellow, Swinburne University of Technology
-
Research Assistant in Psychiatry, University of Cambridge
-
Senior Clinical Lecturer & Consultant Psychiatrist, King's College London
-
Professor, Brain Institute, Universidade Federal do Rio Grande do Norte (UFRN)
-
Universidade Federal do Rio Grande do Norte (UFRN)
-
Assistant Professor, Department of Chemistry; Department of Biochemistry & Molecular Medicine; Center for Neuroscience, University of California, Davis
-
Professor of Neuropsychopharmacology, Imperial College London
-
Associate Professor, Behavioural Pharmacology Research Unit, Johns Hopkins University